【摘要】 目的:探讨紫杉醇联合顺铂与吉西他滨联合顺铂方案治疗晚期非小细胞肺癌的疗效和毒副反应。方法:经病理组织学或细胞学证实的70例晚期非小细胞肺癌,随机分为TP组(紫杉醇+顺铂)和GP组(吉西他滨+顺铂),每组35例。结果:TP组和GP组有效率分别为48.5%(17/35)和45.7%(16/35),组间无显著性差异(P>0.05),中位疾病进展时间分别为3.3个月和4.6个月,组间有显著性差异(P<0.05),中位生存时间分别为8.5个月和9.2个月,组间无显著性差异(P>0.05),一年生存率分别为40%和37.1%,组间无显著性差异(P>0.05);毒副反应以骨髓抑制,胃肠道反应为主,TP组脱发、肌肉关节痛、周围神经炎较为显著,GP组血小板下降较高,两组均有显著性差异。结论:TP组和GP组有效率无显著性差异,各组毒副反应侧重各有不同。更多还原

【Abstract】 Objective:To study the efficacy,toxicity and side effects of Paclitaxel or Gemcitabine Combined with Cisplatin In Treatment of Advanced Non-small Cell Lung Cancer(NSCLC).Methods:70 advanced patients diagnosed by pathology or cytology were enrolled into TP (Paclitaxel+ Cisplatin) and GP (Gemcitabine+ Cisplatin),each group have 35 patients.Results:The efficacy with group TP and GP were 48.5%(17/35) and 37.1%(16/35),respectively.There was no significant difference(P>0.05) between two groups from the view of accounting.The median ailment development time were 3.3 and 4.6 months for group TP and GP,respectively and there had some accounting difference (P<0.05),The median survival time were 8.5 and 9.2 moths and no significant difference appeared (P>0.05),Finally the 1-year survival time were 40.5% for group TP and 37.1% for group GP and there were also no significant difference (P>0.05);The main side effects were myelosuppression、gastrointestinal reactions,The alopecia、pain in muscle and joint、peripheral neuropathy with group TP was little higher than that of group GP,but the thromasthenia with group GP was little higher than that of group TP,respectively and there had some accounting difference.Conclusions:There were no significant difference with group TP and GP on efficacy,the toxicities and side effects with group TP and GP were difference.更多还原